Substance (Drug) Abuse: 2018 Pipeline Insights featuring Cerecor, Addex Therapeutics, Zynerba, InterveXion and Grunenthal Forsee Pharmaceuticals - ResearchAndMarkets.com

The "Substance (Drug) Abuse - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Substance (Drug) Abuse development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Substance (Drug) Abuse pipeline products by developmental stage, product type, molecule type, and administration route.

Scope

• The report provides a snapshot of the pipeline development for the Substance (Drug) Abuse
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Substance (Drug) Abuse
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Substance (Drug) Abuse
• The report also covers the dormant and discontinued pipeline projects related to the Substance (Drug) Abuse

Companies Featured

• Cerecor
• Addex Therapeutics
• Zynerba
• InterveXion
• Grunenthal Forsee Pharmaceuticals

Key Topics Covered

1. Report Introduction

2. Substance (Drug) Abuse Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/m5vqcf/substance_drug?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005795/en/